Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Proteomics Scientist to Head Proteomics Discovery at Syn X Pharma

NEW YORK, Feb 6 – Toronto-based proteomics company Syn X Pharma has appointed Bradley Thatcher as vice president of proteomics discovery, Syn X said Tuesday.

Prior to joining Syn X, Thatcher was a senior field scientist specializing in proteomics and director of special projects for Ciphergen Biosystems of Fremont, Calif., where he designed systems to identify, purify, characterize and sequence proteins for development as drug candidates

Thatcher will head the discovery activities of Syn X's proteomics program, cataloging the protein changes involved in disease, the company said.

" Syn X's ability to attract a candidate of Dr. Thatcher's caliber demonstrates our commitment to being a leader in proteomics ," Sean McNicholas, Syn X CEO, said in a statement.

Syn X's flagship product, the Proteomics Discovery Platform, can be used in pre-clinical and clinical phases to identify responders and non-responders to a particular drug, or to identify patients who will benefit from a medicine earlier in the course of a disease.  

The company currently has several diagnostics in development for cardiovascular diseases including heart failure, hypertension, and diabetes, and central nervous system diseases such as Alzheimer's disease.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.